DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for chondroblastic osteosarcoma — screening already-approved drugs against its 17-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChondroblastic osteosarcoma maps to a 17-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chondroblastic osteosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
axin 1 (AXIN1) — AXIN1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dttdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1DK8 · 1.57 Å · ligand 2,3-DIHYDROXY-1,4-DITHIOBUTANE (DTT). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Indian Journal of Forensic Medicine & Toxicology · 2020 · 0 citations · open access
Chondroblastic Osteosarcoma: A Review
AbstractThe main purpose of this article to present a review on chondroblastic osteosarcomaand its prevalencein the different jawbones of the body. The word osteosarcoma mainly refers to a group of heterogeneousmalignancies that involves bone formation or it can also results due to mesenchymal tissue with evidenceof osteogenic disparity. It has been reported around 25% of the pattern of the chondroblastic osteosarcomasrepresents neoplasms.
Science Futures · 2025 · 0 citations · open access
Chondroblastic Osteosarcoma of the Maxilla: A Rare Case Report
AbstractOsteosarcoma is a malignancy of mesenchymal cells that have the ability to produce osteoid or immature bone. Chondroblastic osteosarcoma as constitute a substantial proportion of all osteosarcomas of the jaws. Some examples may be composed almost entirely of malignant cartilage growing in lobules with only small foci of direct osteoid production by tumor cells being identified. Chondroblastic osteosarcoma is a rare and aggressive type of bone cancer that tends to occur in the long bones of the arms and legs, although it can happen in any bone in the body. The cause of chondroblastic osteosarcoma is unknown, but it has been linked to specific genetic mutations and environmental factors. It is most common in adolescents and young adults and is characterized by malignant cartilage-forming cells. The prognosis for chondroblastic osteosarcoma depends on several factors, including the size of the tumor and its location, how far it has spread, and the patient's age and general health. Treatment typically involves a combination of surgery, chemotherapy, and radiation. Here, we present a rare case of maxillary chondroblastic sarcoma in a 33-year old woman presenting with a mass in the right quadrant of the maxilla. The lesion is sized as 42*25*30mm and is expanded from the lateral incisor tooth region area to the tuberosity in the anteroposterior dimension, from the alveolar crest to the maxillary sinus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
